The Latest Updates from ReSPECT Clinical Trials
AANS Follow-Up
Thank you to everyone who stopped by our booth at the AANS annual meeting to learn more about our ReSPECT Recurrent Glioblastoma and Leptomeningeal Metastases clinical trials! If you missed us and would like more information, you can send us an email at...
LM Acquistition Meeting
Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning's investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...
Musella GBM Patient Webinar
➡️ GLIOBLASTOMA PATIENT WEBINAR ⬅️ Join us as the @MusellaFoundation hosts Dr. Andrew Brenner and Dr. Marc Hedrick in a discussion about the ReSPECT-GBM Phase 2 Clinical Trial for Recurrent Glioblastoma. The webinar will take place May 20 2pm EST with a recording to...
Reminder: AANS 2024
Reminder to come stop by the Plus Therapeutics booth #1057 at the American Association of Neurological Surgeons (AANS) annual conference this weekend in Chicago! Our team will be in the exhibit hall during the entire conference, so come say hello 👋 #AANS2024...
ReSPECT-LM at North Shore
❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of North Shore University Hospital in New York to our ReSPECT-LM Clinical Trial with Principal Investigator Michael Schulder, M.D.. This site is NOW ENROLLING patients. Michael Schulder,...
Brain Tumor Awareness Month
Brain tumor research is at the heart of what we do. Our team focuses every day on how to fight for a cure, and we are passionate about the Brain Cancer community. 🧠🎗️ We have some great education events and news this month that we look forward to sharing with you all,...
PBC Resources
Following our EXCITING NEWS about our $3 Million award recommendation from the United States Department of Defense, we wanted to reshare our cancer guides for Pediatric High-Grade Glioma (https://www.respect-trials.com/patient-guide-hgg/) and Ependymoma...
AANS Conference 2024
Come join us at the American Association of Neurological Surgeons (AANS) Annual Meeting in Chicago, IL next week! Visit our booth to learn about our #clinicaltrials for #patients with recurrent #glioblastoma, leptomeningeal #metastases, & pediatric #braincancer...
Active Award Support for ReSPECT
"Plus Therapeutics' commitment to revolutionizing cancer treatment extends beyond this latest award. With $23 million in active awards support, the company is at the forefront of targeted radiotherapeutic research. Moreover, ongoing trials, including ReSPECT-GBM for...
LBBC Metastatic BC Conference
Thank you to everyone who came by our booth at #LBBCMetsConf this last weekend! If you missed us or would like to learn more about our Leptomeningeal Metastases clinical trial for Metastatic Breast Cancer patients, you can visit our website at...
PBC Funding Award
Exciting news yesterday as $PSTV was able to share our recent $3 Million DoD Award for our ReSPECT-PBC Pediatric Brain Cancer Trial. Stock Region Article: https://bit.ly/4b4OBXG #Nasdaq #ClinicalResearch #ClinicalTrial #PediatricOncology #BrainCancer
$3 Million DoD Grant
BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the...
“Thriving Together”
Come by our NEW booth at the Living Beyond Breast Cancer Metastatic Breast Cancer Conference this weekend! We have information about Leptomeningeal Metastases and our ongoing ReSPECT-LM Clinical Trial. See you there! 🎗️ ReSPECT-LM Website:...
Head for the Cure: North Texas
Join some of the Plus Therapeutics team at the Head for the Cure 5K - North Texas on May 4th! They will be out supporting the local community, cancer research, and "Defeating Brain Cancer Step by Step." We hope to see you there 🏃🏃♂️🏃♀️ Event information:...
Welcome Dr. Brenner!
#ICYMI: Plus Therapeutics added Dr. Andrew Brenner to our management team. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. Full Press...
LBBC Curtain Raiser
📣 Mark Your Calendars! Plus Therapeutics will be exhibiting at the @livingbeyondbc Thriving Together Metastatic Breast Cancer Conference, April 19-21. Come learn about our ReSPECT-LM clinical trial for Leptomeningeal Metastases and meet some of our team. Event...
PSTV Analysis
#ICYMI : "Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst...Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due to a...
https://twitter.com/plustxinc
Welcome Brenner and Blouw
We would like to officially welcome Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. to the Plus Therapeutics Management Team! “As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology,...
NCCN Poster
Our ReSPECT-LM Poster from the National Comprehensive Network (NCCN) Conference is now on our website at https://ir.plustherapeutics.com/presentations
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 AANS Follow-Up
- 1.2 LM Acquistition Meeting
- 1.3 Musella GBM Patient Webinar
- 1.4 Reminder: AANS 2024
- 1.5 ReSPECT-LM at North Shore
- 1.6 Brain Tumor Awareness Month
- 1.7 PBC Resources
- 1.8 AANS Conference 2024
- 1.9 Active Award Support for ReSPECT
- 1.10 LBBC Metastatic BC Conference
- 1.11 PBC Funding Award
- 1.12 $3 Million DoD Grant
- 1.13 “Thriving Together”
- 1.14 Head for the Cure: North Texas
- 1.15 Welcome Dr. Brenner!
- 1.16 LBBC Curtain Raiser
- 1.17 PSTV Analysis
- 1.18
- 1.19 Welcome Brenner and Blouw
- 1.20 NCCN Poster